Paxlovid 10 days for immunologic deficiency syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 20 Oct 2022: Trial registered, NCT05587894
  2. 27 Apr 2023: Trial started, NCT05587894
  3. 27 Apr 2023: Trial started, NCT07406217
  4. 12 Feb 2026: Trial registered, NCT07406217

The trials

NCT05587894: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

State
Under way
Phase
Phase 2
People
256 planned
Started
27 Apr 2023
Primary completion
31 Dec 2026
Arms
Nirmatrelvir/r 10 days alone
Results
None posted
  1. 20 Oct 2022: Trial registered
  2. 27 Apr 2023: Trial started

NCT07406217: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

State
Under way
Phase
Phase 2
People
256 planned
Started
27 Apr 2023
Primary completion
10 Apr 2026
Arms
Nirmatrelvir/ritonavir (nirmatrelvir/r) 10 days alone, Nirmatrelvir/ritonavir (nirmatrelvir/r) 10 days + remdesivir single dose
Results
None posted
  1. 27 Apr 2023: Trial started
  2. 12 Feb 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.